NCT06295614 Study on Preliminary Safety and Efficacy of the ARC-IM Therapy to Alleviate Locomotor Deficits in People With Parkinson's Disease
| NCT ID | NCT06295614 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ecole Polytechnique Fédérale de Lausanne |
| Condition | Parkinson Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 6 participants |
| Start Date | 2024-02-14 |
| Primary Completion | 2029-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 6 participants in total. It began in 2024-02-14 with a primary completion date of 2029-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this clinical trial is to assess the preliminary safety and efficacy of the ARC-IM spinal cord stimulation therapy in alleviating locomotor deficits in individuals with Parkinson's disease. The ARC-IM Therapy employs epidural electrical stimulation (EES) to modulate leg muscle recruitment, with the aim of improving mobility deficits. The ultimate goal is to enhance the quality of life of people with Parkinson's disease.
Eligibility Criteria
Inclusion Criteria: * Typical form of Parkinson's Disease with II-IV Hoehn-Yahr stage with standard therapy, * Suffering from debilitating locomotor deficits, including gait impairments of either postural instability and/or freezing of gait, despite optimal medical management, * 18 years of age or older, * Able to understand and interact with the study team in French or English, * Must use safe contraception for women of childbearing capacity, * Must agree to comply in good faith with all conditions of the study and to attend all required study trainings and visits. * Must provide and sign the study's Informed Consent prior to any study-related procedures. Exclusion Criteria: * Atypical forms of Parkinson's Disease (such as Multiple System Atrophy or Progressive Supranuclear Palsy), * Secondary causes of gait problems independent of Parkinson's Disease, * Inability to follow study procedures, * Unstable or significant medical condition that is likely to interfere with study procedures or likely to confound study endpoint evaluations as determined by the Investigator, * History of major psychiatric disorders or major neurocognitive disorder as considered by the Investigators in accordance with treating physician and treating neurologist, * Major change in PD treatment planned until the end of the main study phase (such as Deep Brain Stimulation or dopamine-pump implantation), * Diseases and conditions that would increase the morbidity and mortality of the implantation surgery, * Spinal anatomical abnormalities precluding surgery, * History of drug or alcohol abuse in the past 5 years, * Life expectancy of less than 12 months, * Pregnant or breast feeding, * Intention to get pregnant during the course of the study, * Indication requiring frequent Magnetic Resonance Imaging (MRI), * Experimental treatment taken in the past 5 years, * Participation in another interventional study, * Enrolment of the investigator, his/her family members, employees, and other dependent persons.
Contact & Investigator
Jocelyne Bloch, MD
PRINCIPAL INVESTIGATOR
Centre hospitalier universitaire vaudois (CHUV)
Frequently Asked Questions
Who can join the NCT06295614 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06295614 currently recruiting?
Yes, NCT06295614 is actively recruiting participants. Contact the research team at jocelyne.bloch@chuv.ch for enrollment information.
Where is the NCT06295614 trial being conducted?
This trial is being conducted at Lausanne, Switzerland.
Who is sponsoring the NCT06295614 clinical trial?
NCT06295614 is sponsored by Ecole Polytechnique Fédérale de Lausanne. The principal investigator is Jocelyne Bloch, MD at Centre hospitalier universitaire vaudois (CHUV). The trial plans to enroll 6 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.